Spots Global Cancer Trial Database for neoadjuvant chemoimmunotherapy

Every month we try and update this database with for neoadjuvant chemoimmunotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer	NCT05496166	Limited Stage S...	chemotherapy an...	18 Years - 70 Years	Shanghai Pulmonary Hospital, Shanghai, China
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC	NCT06288360	Cervical Cancer Locally Advance... PD-L1 Negative Neoadjuvant Che...	Camrelizumab Paclitaxel-albu... Cisplatin radical surgery	18 Years - 70 Years	Tongji Hospital
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma	NCT05740995	Esophageal Squa... Neoadjuvant Che...	neoadjuvant ant...	18 Years - 75 Years	Shanghai Zhongshan Hospital
The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer	NCT02976142	Gastric Cancer,...	neoadjuvant che...	18 Years - 80 Years	Moscow Clinical Scientific Center
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer	NCT06289751	Cervical Cancer Neoadjuvant Che... Radical Hystere... Fertility Prese...	Cadonilimab Paclitaxel-albu... Cisplatin Extrafascial hy...	18 Years - 70 Years	Tongji Hospital
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer	NCT06289062	Cervical Cancer Neoadjuvant Che... Fertility Prese...	Camrelizumab Cisplatin Nab paclitaxel biopsy	18 Years - 45 Years	Tongji Hospital
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma	NCT06056336	Esophageal Squa... Neoadjuvant Che... Adjuvant Therap...	Tislelizumab	18 Years - 75 Years	Shanghai Chest Hospital
Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy	NCT06285058	Deep Learning M... Pathological Co... Non-small Cell ... Neoadjuvant Che...	No intervention...	18 Years - 80 Years	Wuhan Union Hospital, China
Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy	NCT06285058	Deep Learning M... Pathological Co... Non-small Cell ... Neoadjuvant Che...	No intervention...	18 Years - 80 Years	Wuhan Union Hospital, China
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma	NCT06436040	Tumor Microenvi... Lung Squamous C... Neoadjuvant Che...	Pathological re...	40 Years - 80 Years	Tang-Du Hospital
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma	NCT06056336	Esophageal Squa... Neoadjuvant Che... Adjuvant Therap...	Tislelizumab	18 Years - 75 Years	Shanghai Chest Hospital
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma	NCT06436040	Tumor Microenvi... Lung Squamous C... Neoadjuvant Che...	Pathological re...	40 Years - 80 Years	Tang-Du Hospital
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC	NCT06288373	Cervical Cancer Locally Advance... Concurrent Chem... Neoadjuvant Che...	Camrelizumab Cisplatin Nab paclitaxel Radical surgery external beam r... Cisplatin	18 Years - 70 Years	Tongji Hospital
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma	NCT05503667	Lung Adenocarci... Lung Adenocarci... EGFR Gene Mutat...	Furmonertinib Bevacizumab	18 Years -	Shanghai Pulmonary Hospital, Shanghai, China
Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer	NCT05925751	Non-small Cell ... Neoadjuvant Che... Complete Pathol...	CT/PET/WSI-base...	20 Years - 75 Years	Shanghai Pulmonary Hospital, Shanghai, China
Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial	NCT05763992	Breast Cancer Triple Negative... Dietary Exposur... Fasting	Control diet (A...	18 Years - 75 Years	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer	NCT05925751	Non-small Cell ... Neoadjuvant Che... Complete Pathol...	CT/PET/WSI-base...	20 Years - 75 Years	Shanghai Pulmonary Hospital, Shanghai, China
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma	NCT05503667	Lung Adenocarci... Lung Adenocarci... EGFR Gene Mutat...	Furmonertinib Bevacizumab	18 Years -	Shanghai Pulmonary Hospital, Shanghai, China
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer	NCT06289062	Cervical Cancer Neoadjuvant Che... Fertility Prese...	Camrelizumab Cisplatin Nab paclitaxel biopsy	18 Years - 45 Years	Tongji Hospital
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma	NCT06436040	Tumor Microenvi... Lung Squamous C... Neoadjuvant Che...	Pathological re...	40 Years - 80 Years	Tang-Du Hospital
Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial	NCT05763992	Breast Cancer Triple Negative... Dietary Exposur... Fasting	Control diet (A...	18 Years - 75 Years	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy	NCT06285058	Deep Learning M... Pathological Co... Non-small Cell ... Neoadjuvant Che...	No intervention...	18 Years - 80 Years	Wuhan Union Hospital, China
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer	NCT06289751	Cervical Cancer Neoadjuvant Che... Radical Hystere... Fertility Prese...	Cadonilimab Paclitaxel-albu... Cisplatin Extrafascial hy...	18 Years - 70 Years	Tongji Hospital
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma	NCT05740995	Esophageal Squa... Neoadjuvant Che...	neoadjuvant ant...	18 Years - 75 Years	Shanghai Zhongshan Hospital
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma	NCT05503667	Lung Adenocarci... Lung Adenocarci... EGFR Gene Mutat...	Furmonertinib Bevacizumab	18 Years -	Shanghai Pulmonary Hospital, Shanghai, China

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: